172 related articles for article (PubMed ID: 29466692)
1. Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma -- a clinical update.
Trinh VA; Joseph J; Hwu WJ
Discov Med; 2018 Jan; 25(135):31-40. PubMed ID: 29466692
[TBL] [Abstract][Full Text] [Related]
2. Resistance to PD-1 blockade in melanoma.
Burki TK
Lancet Oncol; 2016 Sep; 17(9):e376. PubMed ID: 27452143
[No Abstract] [Full Text] [Related]
3. Nivolumab: A Review in Advanced Melanoma.
Scott LJ
Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
5. [Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma].
Adam J; Tomasic G; Robert C
Ann Pathol; 2017 Feb; 37(1):55-60. PubMed ID: 28111041
[TBL] [Abstract][Full Text] [Related]
6. Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma.
Metcalfe W; Anderson J; Trinh VA; Hwu WJ
Discov Med; 2015 May; 19(106):393-401. PubMed ID: 26105702
[TBL] [Abstract][Full Text] [Related]
7. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
[No Abstract] [Full Text] [Related]
8. Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma.
Moser JC; Wei G; Colonna SV; Grossmann KF; Patel S; Hyngstrom JR
Acta Oncol; 2020 Apr; 59(4):434-437. PubMed ID: 31920132
[No Abstract] [Full Text] [Related]
9. Outcomes of retreatment with anti-PD-1 monotherapy after response to first course in patients with cutaneous melanoma.
Whitman ED; Scherrer E; Ou W; Krepler C
Future Oncol; 2020 Jul; 16(20):1441-1453. PubMed ID: 32410465
[No Abstract] [Full Text] [Related]
10. TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma.
Bertrand F; Montfort A; Marcheteau E; Imbert C; Gilhodes J; Filleron T; Rochaix P; Andrieu-Abadie N; Levade T; Meyer N; Colacios C; Ségui B
Nat Commun; 2017 Dec; 8(1):2256. PubMed ID: 29273790
[TBL] [Abstract][Full Text] [Related]
11. Focal regression of a primary melanoma, fading lentigines and poliosis in metastatic melanoma treated with anti-PD-1.
Thomas S; Laino A; Sturm R; Nufer K; Lambie D; Shepherd B; Atkinson V; Adams L; Soyer HP; Schaider H
J Eur Acad Dermatol Venereol; 2018 May; 32(5):e176-e177. PubMed ID: 29114959
[No Abstract] [Full Text] [Related]
12. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
Ashida A; Sakaizawa K; Uhara H; Okuyama R
Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
[TBL] [Abstract][Full Text] [Related]
13. PD-1 inhibition in congenital pigment synthesizing metastatic melanoma.
Weyand AC; Mody RJ; Rabah RM; Opipari VP
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28675691
[TBL] [Abstract][Full Text] [Related]
14. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
Zimmer L; Apuri S; Eroglu Z; Kottschade LA; Forschner A; Gutzmer R; Schlaak M; Heinzerling L; Krackhardt AM; Loquai C; Markovic SN; Joseph RW; Markey K; Utikal JS; Weishaupt C; Goldinger SM; Sondak VK; Zager JS; Schadendorf D; Khushalani NI
Eur J Cancer; 2017 Apr; 75():47-55. PubMed ID: 28214657
[TBL] [Abstract][Full Text] [Related]
15. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
Gutzmer R; Koop A; Meier F; Hassel JC; Terheyden P; Zimmer L; Heinzerling L; Ugurel S; Pföhler C; Gesierich A; Livingstone E; Satzger I; Kähler KC;
Eur J Cancer; 2017 Apr; 75():24-32. PubMed ID: 28214654
[TBL] [Abstract][Full Text] [Related]
16. Complete regression of a previously untreated melanoma brain metastasis with ipilimumab.
Schartz NE; Farges C; Madelaine I; Bruzzoni H; Calvo F; Hoos A; Lebbé C
Melanoma Res; 2010 Jun; 20(3):247-50. PubMed ID: 20216240
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint blockade in patients with melanoma metastatic to the brain.
Di Giacomo AM; Margolin K
Semin Oncol; 2015 Jun; 42(3):459-65. PubMed ID: 25965364
[TBL] [Abstract][Full Text] [Related]
18. The role of ipilimumab after anti-PD-1 treatment: two case reports and a literature review.
Ros-Montañá J; Saoudi-Gonzalez N; Ortiz-Velez C; Muñoz-Couselo E
Melanoma Res; 2020 Apr; 30(2):209-212. PubMed ID: 31348136
[TBL] [Abstract][Full Text] [Related]
19. The forgotten role of adjuvant immune checkpoint inhibitors in preventing melanoma brain metastasis.
El Rassy E; Farhat F; Kattan J
Immunotherapy; 2018 Nov; 10(15):1289-1291. PubMed ID: 30474477
[No Abstract] [Full Text] [Related]
20. What to Do When Anti-PD-1 Therapy Fails in Patients With Melanoma.
Mooradian MJ; Sullivan RJ
Oncology (Williston Park); 2019 Apr; 33(4):141-8. PubMed ID: 30990567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
